RIÑÓN Y ENFERMEDAD CARDIOVASCULAR - Seden

BIBLIOGRAFÍA
293. Kasiske BL, Guijarro C, Massy Z,Wiederkehr MR, Ma JZ.
Cardiovascular disease after renal transplantation. J Am Soc
Nephrol 7: 158-65, 1996.
294. United States Renal Data System. USRDS 2002; Annual Data
Report. Bethesda MD: The National Institutes of Health,
National Institute of Diabetes and Digestive and Kidney
Diseases. Available at: http://www.usrds.org/reference.htm,
2002
295. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE,
Martin A, Klag MJ.Traditional cardiovascular disease risk factors
in dialysis patients compared with the general population:
the CHOICE Study. J Am Soc Nephrol13:1918-27,
2002.
296. Cheung AK, Sarnak MJ, Yang G, Dwyer JT, Heyka RJ, Rocco
MV y cols. Atherosclerotic cardiovascular disease risks in
chronic hemodialysis patients. Kidney Int 58: 353-62, 2000.
297. Locatelli F, Pozzoni P, Tentori F, del Vecchio L.Epidemiology
of cardiovascular risk in patients with chronic kidney disease.
Nephrol Dial Transplant.18 (Suppl 7):S2-S9, 2003.
298. Zoccali C, Mallamaci F, Tripepi G. Novel Cardiovascular
Risk Factors in End-Stage Renal Disease. J Am Soc Nephrol
15 (supl 1): S77-S80, 2004.
299. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained
ischemic heart disease risk after renal transplantation. J
Am Soc Nephrol 11:1735-43, 2000.
300. Jindal RM, Hjelmesæth J. Impact and management of posttransplant
diabetes mellitus. Transplantation 70 (11 Suppl):
SS58–SS63, 2000.
301. Torregrosa JV. Cardiovascular risk and diabetogenicity associated
with CNI use: a comparison between cyclosporine
and tacrolimus. Transplant Int 2004 (en prensa)
302. Culleton BF, Wilson PW. Cardiovascular disease: risk factors,
secular trends, and therapeutic guidelines. J Am Soc Nephrol
9: S5–15, 1998.
303. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S,
Mendelssohn D, y cols. Left ventricular mass index increase
in early renal disease: impact of decline in hemoglobin. Am
J Kidney Dis 27: 347-54, 1996.
304. McMahon LP, Roger SD, Levin A, for the Slimheart
Investigators group. Development, prevention, and potential
reversal of left ventricular hypertrophy in chronic kidney
disease. J Am Soc Nephrol 15: 1640-47, 2004.
305. Wheeler DC, Townend JN, Landray MJ. Cardiovascular risk
factors in predialysis patients: baseline data from the
Chronic Renal Impairment in Birmingham (CRIB) study.
Kidney Int (Supl. 84): S201-3, 2003.
306. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC,
Barre PE. Outcome and risk factors for left ventricular disorders
in chronic uremia. Nephrol Dial Transplant 11: 1277-
1285, 1996.
307. Silberberg JS, Barre P, Prichard SS, Sniederman AD. Impact
of left ventricular hypertrophy on survival in end-stage renal
disease. Kidney Int 36: 286-290, 1989.
308. London GM, Pannier B, Guerin P, Blacher J, Marchais SJ,
Darne B. Alterations of left ventricular hypertrophy in and
survival of patients receiving hemodialysis: Follow-up of an
interventional study. J Am Soc Nephrol 12: 2759-67, 2001.
309. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC,
Barre PE.Long-term evolution of cardiomyopathy in dialysis
patients. Kidney Int. 54:1720-5, 1998.
310. Huting J, Kramer W, Schütterle G, Wizemann V. Analysis of
left ventricular changes associated with chronic hemodialysis.
Nephron 49: 284-90, 1998.
311. Parfrey PS, Harnett JD, Foley RN, Kent GM, Murray DC,
Barre PE, Guttmann RD. Impact of renal transplantation on
uremic cardiomyopathy. Transplantation:60: 908-14, 1995.
312. Rigatto C, Foley RN, Kent GM, Guttmann R, Parfrey PS.
Long-term changes in left ventricular hypertrophy after renal
transplantation. Transplantation 70:570-5, 2000.
313. Brahimi M, Dahan M, Dabire H, Levy BI. Impact of pulse
pressure on degree of cardiac hypertrophy in patients with
chronic uremia. J Hypertens 18: 1645-50, 2000.
314. Ventura JE, Tavella N, Romero C, Petraglia A, Baez A, Munoz
L. Aortic valve calcification is an independent factor of left
ventricular hypertrophy in patients on maintenance hemodialysis.
Nephrol Dial Transplant 17: 1795-801, 2002.
315. London GM, Guerin AP, Marchais SJ, Pannier B, Safar M,
Day M, y cols. Cardiac and arterial interactions in end-stage
renal disease. Kidney Int 50: 600-608, 1996.
316. Nitta K, Akiba T, Uchida K, Otsub S, Otsubo Y, Takei T y cols.
Left ventricular hypertrophy is associated with arterial stiffness
and vascular calcification. Hypertens Res 27: 47-52,
2004.
317. Fagugli RM, Pasini P, Quintaliani G, Pasticci F, Ciao G,
Cicconi B, y cols. Association between extracellular water,
left ventricular mass and hypertension in haemodialysis
patients. Nephrol Dial Transplant. 18:2332-8, 2003.
318. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Candela V,
Labate C, Tassone F.Left ventricular hypertrophy and nocturnal
hypoxemia in hemodialysis patients. J Hypertens 19:287-
93, 2001.
319. Hernandez D, Lacalzada J, Barragan A, Laynez I, Salido E,
Barrios Y, y cols. Hipertrofia ventricular izquierda después
del trasplante renal: prevención y tratamiento. Nefrología
24(supl IV): S43-S48, 2004.
320. Ritz E, Rambausek M, Mall G, Rufmann K, Mandelbaum A.
Cardiac changes in uraemia and their possible relationship
to cardiovascular instability on dialysis. Nephrol Dial
Transplant 5(supl 1): 93-97, 1990.
321. Roig E, Betriu A, Castaner A, Magrina J, Sanz G, Navarro-
Lopez F. Disabling angina pectoris with normal coronary
arteries in patients undergoing long-term hemodialysis. Am J
Med. 71:431-4, 1981.
322. Mall G, Huther W, Schneider J, Lundin P, Ritz E. Diffuse
intermyocardiocytic fibrosis in uremic patients. Nephrol Dial
Transplant 5: 39-44, 1990.
323. Zoccali C, Benedetto FA, Mallamaci T, y cols. Prognostic
impact of the indexation of left ventricular mass in patients
undergoing dialysis. J Am Soc Nephrol 12: 2768-2774,
2001.
324. Stack AG, Saran R. Clinical correlates and mortality impact
of left ventricular hypertrophy among new ESRD patients in
the United States. Am J Kidney Dis. 40:1202-10, 2002.
325. Fathi R, Isbel N, Haluska B, Case C, Johnson DW, Marwick
TH.: Correlates of subclinical left ventricular dysfunction in
ESRD. Am J Kidney Dis 41: 1016-1025, 2003.
326. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC,
Barre PE. The impact of anemia on cardiomyopathy, morbidity,
and mortality in end-stage renal disease. Am J Kidney
Dis 28: 53-61, 1996.
196